Tretten Approved for Genetic Clotting Disorder
Posted by AMS Staff on Jan 02, 2014 in medical | 0 comments
The FDA has approved Tretten (coagulation factor XIII A-subunit [recombinant]; Novo Nordisk) for use in the routine prevention of bleeding in adults and children who have congenital Factor XIII A-subunit deficiency, a rare clotting disorder. Tretten is the first recombinant product approved for this indication. RELATED: Hematological Disorders Resource Center Tretten is a recombinant analog of… Read More »
[...]
0